Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK-J4 (GSK J4 HCl) 是 H3K27me3/me2 去甲基化酶JMJD3/KDM6B 和UTX/KDM6A 双抑制剂,IC50分别为 8.6 μM 和 6.6 μM。它是 GSK-J1 的细胞通透性前药,可诱导内质网应激相关的细胞凋亡。它抑制 LPS 诱导的人原代巨噬细胞产生 TNF-α,IC50值为 9 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 397 | 现货 | ||
5 mg | ¥ 617 | 现货 | ||
10 mg | ¥ 956 | 现货 | ||
25 mg | ¥ 1,840 | 现货 | ||
50 mg | ¥ 2,996 | 现货 | ||
100 mg | ¥ 3,770 | 现货 | ||
200 mg | ¥ 5,420 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,098 | 现货 |
产品描述 | GSK-J4 (GSK J4 HCl) is a potent H3K27me3 demethylase inhibitor, with IC50s of 8.6 μM and 6.6 μM towards KDM6B and KDM6A respectively. It is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and inactive against a panel of demethylases of the JMJ family. |
靶点活性 | JMJD3: |
体内活性 | GSK-J4 (0.5 mg/kg, i.p.) significantly reduces the severity and delays the onset of the disease of the mouse model of experimental autoimmune encephalomyelitis[2]. |
动物实验 | GSK-J4 is prepared in DMSO and diluted 1/10 with ethanol.Six-to eight-week-old female C57BL/6 WT mice are injected by subcutaneous injection (s.c.) with 50 μg myelin oligodendrocyte glycoprotein 35-55 peptide (pMOG) emulsified in Complete Freund's Adjuvant (CFA) supplemented with heat-inactivated Mycobacterium tuberculosis H37 RA. In addition, mice receive intraperitoneal injection (i.p.) of 500 ng of pertussis toxin on days 0 and 2. Clinical signs are assessed daily according to the following scoring criteria: 0, no detectable signs; 1, flaccid tail; 2, hind limb weakness or abnormal gait; 3, complete hind limb paralysis; 4, paralysis of fore and hind limbs; and 5, moribund or death. A stock solution of GSK-J4 of 42 mg/mL (100 mM) is prepared in dimethyl sulfoxide (DMSO) to preserve stability. Before injection, the stock solution is diluted 1/10 with ethanol (DMSO: ethanol, 1:10 v/v) and brought to a final concentration of 140 μg/mL in PBS. In systemic drug evaluation experiments, each mouse receive daily i.p. injections (from days 0-5) of 100 μL of this solution containing 14.0 μg of the GSK-J4 (equivalent to 0.56 mg/kg of the drug). Control mice receive 100 μL of the vehicle during the same period. In other EAE experiments, 106 bone marrow-derived DCs from WT mice are treated with GSK-J4 or vehicle alone for 16 h, pulsed with 5 μg/mL of pMOG for 4 h and then transferred i.v. into WT C57BL/6 recipient mice 14 and 7 days before EAE induction. In other adoptive transfer EAE experiments, CD4+Foxp3+ Treg cells generated in the presence or absence of 25 nM GSK-J4 are purified by cell sorting and then 0.75×106 transferred i.v. into WT C57BL/6 recipient mice 1 day before EAE induction. |
别名 | GSK J4 HCl |
分子量 | 417.5 |
分子式 | C24H27N5O2 |
CAS No. | 1373423-53-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 41.75 mg/ml(100 mM)
DMSO: 41.75 mg/ml(100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.3952 mL | 11.976 mL | 23.9521 mL | 59.8802 mL |
5 mM | 0.479 mL | 2.3952 mL | 4.7904 mL | 11.976 mL | |
10 mM | 0.2395 mL | 1.1976 mL | 2.3952 mL | 5.988 mL | |
20 mM | 0.1198 mL | 0.5988 mL | 1.1976 mL | 2.994 mL | |
50 mM | 0.0479 mL | 0.2395 mL | 0.479 mL | 1.1976 mL | |
100 mM | 0.024 mL | 0.1198 mL | 0.2395 mL | 0.5988 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
GSK-J4 1373423-53-0 Apoptosis Chromatin/Epigenetic Histone Demethylase GSKJ4 Inhibitor H3K27me3/me2 demethylase diabetic inflammation Th17 TGF-β mice cells dendritic GSK-J-4 inhibit Th1 GSK J4 HCl GSK J4 inhibitor